(Q38220364)

31 August 2017

title

Belgian consensus on metabolic problems associated with atypical antipsychotics (English)

1 reference

31 August 2017

A De Nayer

1

1 reference

31 August 2017

M De Hert

2

1 reference

31 August 2017

A Scheen

3

1 reference

31 August 2017

L Van Gaal

4

1 reference

31 August 2017

J Peuskens

5

1 reference

31 August 2017

On Behalf Of The Consensus Group

6

1 reference

31 August 2017

A De Nayer

7

1 reference

31 August 2017

M De Hert

8

1 reference

31 August 2017

A Scheen

9

1 reference

31 August 2017

L Van Gaal

10

1 reference

31 August 2017

J Peuskens

11

1 reference

31 August 2017

On Behalf Of The Consensus Group

12

1 reference

31 August 2017

publication date

1 January 2005

1 reference

International Journal of Psychiatry in Clinical Practice

31 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

31 August 2017

volume

9

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

130-137

1 reference

Consensus development conference on antipsychotic drugs and obesity and diabetes

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Diabetes mellitus in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Relationship of atypical antipsychotics with development of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Diabetes Mellitus Associated with Atypical Anti-Psychotic Medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Atypical antipsychotics and glucose dysregulation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Glucose intolerance with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Clozapine-associated diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Olanzapine-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Risperidone-associated diabetes mellitus: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

The homeostasis model in the San Antonio Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

Lowering the criterion for impaired fasting glucose is in order

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13651500510018310

10.1080/13651500510018310

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference